Clinical trial NCT04924946: Current Use in Intensive Care Units by Intensivists of Antihypertensive Drugs
Official title: Current Use in Intensive Care Units by Intensivists of Antihypertensive Drugs
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Antihypertensive Drugs in ICU
Keywords: intensive care
antihypertensive drugs
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2021-06-14
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adult patients hospitalized in intensive care

Brief summary: Multicenter, prospective and observational study of practices and impacts of the use of antihypertensive therapies in intensive medicine and intensive care

Detailed description: Multicenter, prospective observational cohort study on 200 patients, by doctor's questionnaire on the prescription of antihypertensive drugs in intensive care, follow-up over 72 hours of the prescription.

Eligibility criteria: Inclusion Criteria:

* Adult patient
* Admitted to an intensive care unit
* Patient having presented a state of circulatory shock, defined by the need for continuous administration of a vasopressive amine for at least one hour, among: Noradrenaline, Adrenaline
* In whom the introduction of drug treatment for antihypertensive purposes is decided

Exclusion Criteria:

* Patient admitted to intensive care for a hypertensive emergency (hypertensive surge or malignant arterial hypertension leading to organ dysfunction
* Patient who has already received at least one anti-hypertensive drug during his stay in intensive care
* Cerebro-injured patient, proven or suspected cerebral edema, head trauma \<1 month, decrease in cerebral perfusion measured
* Proven or suspected active bleeding
* Patient refusal of participation

Primary outcomes:
measure: Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings
timeFrame: 60 days after inclusion
measure: Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings
timeFrame: 60 days after inclusion
measure: Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings
timeFrame: 60 days after inclusion
measure: Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings
timeFrame: 60 days after inclusion
measure: Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings
timeFrame: 60 days after inclusion
measure: Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings
timeFrame: 60 days after inclusion
Secondary outcomes:
measure: Search for efficiency differences between the different molecules
timeFrame: 60 days after inclusion
measure: Search for efficiency differences between the different molecules
timeFrame: 60 days after inclusion
measure: Search for efficiency differences between the different molecules
timeFrame: 60 days after inclusion
measure: Search for efficiency differences between the different molecules
timeFrame: 60 days after inclusion
measure: Search for efficiency differences between the different molecules
timeFrame: 60 days after inclusion
measure: Search for efficiency differences between the different molecules
timeFrame: 60 days after inclusion
measure: Search for differences in side effects between the different molecules
timeFrame: 60 days after inclusion
measure: Search for differences in side effects between the different molecules
timeFrame: 60 days after inclusion
measure: Search for differences in side effects between the different molecules
timeFrame: 60 days after inclusion
Other outcomes:
Locations:
city: Argenteuil
country: France
facility: Intensive Care Victor Dupouy Hospital
city: Bobigny
country: France
facility: Intensive Care Avicenne Hsopital
city: Colombes
country: France
facility: Intensive Care Louis Mourier Hospital
city: Longjumeau
country: France
facility: Intensive Care Longjumeau Hospital
city: Paris
country: France
facility: Intensive Care Bichat Hospital
city: Pontoise
country: France
facility: Intensive Care René Dubos Hospital
city: Tours
country: France
facility: Intensive Care Tours Hospital
Study officials:
References: